Frazier Life Sciences Management, L.P. 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Frazier Life Sciences Management, L.P. disclosed 50 US equity positions worth $2.4bn in its Q4 2024 13F filing. The largest position was NEWAMSTERDAM PHARMA COMPANY at 17.0% of the reported book, followed by MIRM and VRNA. Against the Q3 2024 filing, it opened 3 new positions, added to 12 and reduced 8 among the top 50 holdings.
What did Frazier Life Sciences Management, L.P. own in Q4 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | NEWAMSTERDAM PHARMA COMPANY | 17.0% | $409.1m | 15,916,418 | 24% | added | |
| 2 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 11.3% | $271.7m | 6,570,392 | 0% | held |
| 3 | VRNA VERONA PHARMA PLC | 6.5% | $157.2m | 3,383,950 | 0% | held | |
| 4 | KRYS KRYSTAL BIOTECH INC | Healthcare | 5.1% | $123.5m | 788,460 | -20% | reduced |
| 5 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 5.1% | $122.4m | 8,785,284 | 0% | held |
| 6 | IRON DISC MEDICINE INC | Healthcare | 4.6% | $111.3m | 1,754,834 | 0% | held |
| 7 | MBX MBX BIOSCIENCES INC | Healthcare | 4.6% | $110.3m | 5,985,347 | 0% | held |
| 8 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 4.3% | $104.7m | 1,869,808 | -23% | reduced |
| 9 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 4.3% | $104.3m | 3,800,457 | 1% | added |
| 10 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 3.6% | $87.9m | 1,587,527 | 0% | held |
| 11 | PHAT PHATHOM PHARMACEUTICALS INC | 3.4% | $82.1m | 10,109,279 | 0% | held | |
| 12 | ERAS ERASCA INC | Healthcare | 2.0% | $48.7m | 19,391,687 | 0% | held |
| 13 | PCVX VAXCYTE INC | Healthcare | 1.8% | $44.2m | 539,405 | -39% | reduced |
| 14 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.8% | $43.9m | 10,664,774 | 44% | added |
| 15 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.8% | $43.6m | 997,455 | 0% | held |
| 16 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.7% | $41.4m | 4,887,867 | 33% | added | |
| 17 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 1.5% | $35.2m | 1,069,754 | 2% | added |
| 18 | EWTX EDGEWISE THERAPEUTICS INC | 1.4% | $33.9m | 1,271,245 | -55% | reduced | |
| 19 | SLNOEUR SOLENO THERAPEUTICS INC | 1.3% | $31.4m | 699,159 | -20% | reduced | |
| 20 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.3% | $31.4m | 3,888,238 | -6% | reduced |
| 21 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.2% | $27.7m | 658,715 | 4% | added |
| 22 | SVRA SAVARA INC | Healthcare | 1.1% | $26.6m | 8,660,379 | 6% | added |
| 23 | CGON CG ONCOLOGY INC | Healthcare | 0.9% | $22.1m | 770,000 | 0% | held |
| 24 | HILLEVAX INC | 0.9% | $22.0m | 10,617,062 | 0% | held | |
| 25 | ANAB ANAPTYSBIO INC | Healthcare | 0.9% | $20.8m | 1,573,719 | -29% | reduced |
| 26 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.8% | $18.6m | 1,479,025 | -0% | held |
| 27 | ASND ASCENDIS PHARMA A/S | Healthcare | 0.8% | $18.4m | 133,333 | 0% | held |
| 28 | MREO MEREO BIOPHARMA GROUP PLC | Healthcare | 0.7% | $17.8m | 5,097,779 | 0% | held |
| 29 | ALKS ALKERMES PLC | Healthcare | 0.7% | $17.3m | 601,129 | 4% | added |
| 30 | MERUS N V | 0.7% | $15.7m | 373,100 | 0% | held | |
| 31 | IMTX IMMATICS N.V | Healthcare | 0.6% | $15.3m | 2,147,911 | 59% | added |
| 32 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 0.6% | $14.8m | 1,120,803 | – | new |
| 33 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 0.5% | $12.1m | 1,953,547 | 3% | added |
| 34 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.5% | $11.3m | 583,327 | 22% | added |
| 35 | AUTL AUTOLUS THERAPEUTICS PLC | Healthcare | 0.5% | $10.9m | 4,623,324 | 0% | held |
| 36 | MGNX MACROGENICS INC | Healthcare | 0.4% | $10.3m | 3,175,665 | 5% | added |
| 37 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 0.4% | $8.7m | 689,655 | 0% | held | |
| 38 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 0.4% | $8.6m | 470,338 | 0% | held |
| 39 | SLN SILENCE THERAPEUTICS PLC | 0.3% | $7.9m | 1,148,591 | 0% | held | |
| 40 | PVLA PALVELLA THERAPEUTICS INC NE | 0.3% | $7.8m | 653,892 | – | new | |
| 41 | ETNBGBP 89BIO INC | 0.3% | $7.8m | 1,000,000 | 0% | held | |
| 42 | COGT COGENT BIOSCIENCES INC | Healthcare | 0.3% | $7.3m | 936,576 | 0% | held |
| 43 | NEWAMSTERDAM PHARMA COMPANY | 0.3% | $7.1m | 500,333 | 0% | held | |
| 44 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 0.3% | $6.3m | 955,515 | -24% | reduced |
| 45 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 0.3% | $6.1m | 2,867,750 | 0% | held |
| 46 | ARVN ARVINAS INC | Healthcare | 0.2% | $5.5m | 285,331 | 0% | held |
| 47 | AVU0 ADVERUM BIOTECHNOLOGIES INC | 0.2% | $5.0m | 1,069,244 | 0% | held | |
| 48 | ELDN ELEDON PHARMACEUTICALS INC | 0.2% | $4.8m | 1,176,735 | – | new | |
| 49 | ELEVATION ONCOLOGY INC | 0.1% | $3.4m | 5,993,579 | 0% | held | |
| 50 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 0.1% | $3.2m | 108,762 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.